Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/bcpt.70054 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Patterns of Analgesic Prescribing and High-Risk Prescribing in Primary Care in Ireland 2014-2022-A Repeated Cross-Sectional Study.
Eur J Pain
October 2025
School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
Background: Pain is a significant burden on individuals, healthcare systems and society. Analgesic drugs carry many therapeutic benefits; however, all drugs are associated with adverse effects and risk of harm. Non-steroidal anti-inflammatory drugs (NSAIDs) and opioids have been identified as particularly high-risk due to the risk of side effects and/or dependency.
View Article and Find Full Text PDFShared decision-making and deprescribing to support anti-thrombotic therapy (dis)continuance for persons living with cancer in their last phase of life: A realist synthesis.
PLoS Med
August 2025
Wolfson Palliative Care Research Centre, Hull York Medical School, University of Hull, Hull, United Kingdom.
Introduction: Patients with cancer are at increased risk of thrombotic complications from both the disease and its treatments, with antithrombotic therapy (ATT) usually continued in the last phase of life where the benefit is less clear and there is high risk of harms. Physiological changes toward the end of life increase the risk that ATT will cause serious bleeding events, but discussion between clinicians and patients of ATT risks and benefits is sub-optimal. This realist synthesis explores shared decision-making (SDM) to: (a) provide insights into why prescribing continues in end-of-life care; (b) build a conceptual platform for optimizing ATT prescribing for persons living with cancer towards end-of-life.
View Article and Find Full Text PDFKetogenic Diet as Protection for Deprescribing Antipsychotics.
Schizophr Bull
August 2025
Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Carl-Neuberg-Straße 1, 30625 Hannover, Germany.
People with schizophrenia or schizoaffective disorder are almost always treated with continued use of antipsychotics. Tapering of antipsychotics is very often associated with a recurrence of symptoms within a year. This applies particularly to the final steps of reduction from very small doses.
View Article and Find Full Text PDFCardiac Medications Continuation Versus Discontinuation at End-of-Life: A Retrospective Analysis of Clinical Outcomes.
Am J Hosp Palliat Care
August 2025
Division of Geriatrics and Palliative Medicine, Department of Medicine, Zucker School of Medicine at Hofstra Northwell, Manhasset, NY, USA.
BackgroundInformation regarding cardiac medication management for patients with Heart Failure, Atrial Fibrillation, and Coronary Artery Disease at end of life (EOL) is limited. This study evaluated symptoms and medication utilization patterns at EOL.MethodsRetrospective review of cardiac patients admitted to a palliative care unit (PCU) at a quaternary center in New York.
View Article and Find Full Text PDFClozapine Dose Reduction in Remitted Patients With Treatment-Resistant Schizophrenia: A Case Series.
Schizophr Bull
August 2025
Schizophrenia Division, Centre for Addiction and Mental Health (CAMH), 1051 Queen Street West, Toronto, Ontario M6J 1H3, Canada.
Background: There is limited evidence on the outcomes of clozapine deprescribing in remitted treatment-resistant schizophrenia (TRS) patients. We present a series of TRS patients in remission who underwent progressive reductions in their maintenance clozapine dose.
Study Design: This was a retrospective chart review of patients treated with clozapine from March 20, 2014 to March 20, 2024, at the Centre for Addiction and Mental Health, Toronto, Canada.